Format

Send to

Choose Destination
Intensive Care Med. 2001 Jun;27(6):1083-6.

Somatostatin: a new therapeutic option for the treatment of chylothorax.

Author information

1
Department of Neonatology and Intensive Care, University Children's Hospital, Zurich, Switzerland. vera.buettiker@kispi.unizh.ch

Abstract

BACKGROUND:

The standard treatment of chylothorax in pediatric intensive care today includes conservative therapy with fat-free nutrition, total parenteral nutrition and, if this is not successful, operative treatment (pleurodesis, ligation of the duct, pleuroperitoneal shunt).

PATIENTS:

We describe four patients who were not in a suitable condition for operative treatment and who were treated with continuous infusion of somatostatin.

RESULTS:

In three patients, chylothorax ceased with the continuous somatostatin infusion without side effects. One patient was treated without success.

CONCLUSIONS:

Somatostatin is a therapeutic option for treatment of chylothorax and could reduce surgical intervention and hospitalization time, as well as allow earlier enteral feeding.

PMID:
11497142
DOI:
10.1007/s001340100959
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center